第十九届中国医师协会皮肤科医师年会暨全国美容皮肤科学大会（China Dermatologist Association & National Congress of Cosmetic Dermatology，CDA&NCCD）于2024年11月28日~12月1日在武汉召开，呈现了精彩纷呈的皮肤领域学术盛宴。
注：AE，不良事件；SAE，严重不良事件；EAER，暴露调整事件发生率；E/100PY，每100患者年的发生事件；PY，患者年；UPA，乌帕替尼；TCS，外用糖皮质激素
图1 乌帕替尼治疗中国特应性皮炎人群长达4.3年的暴露调整不良事件发生率（数据来源：参考文献6）
注：*不包括结核病和带状疱疹；**MACE，主要心血管不良事件，定义为心血管死亡、非致命性心肌梗死和非致命性卒中；***VTE，静脉血栓栓塞事件，定义为深静脉血栓和肺栓塞（致命性和非致命性）；EAER，暴露调整事件发生率；EAIR，暴露调整发病率；E/100PY，每100患者年的发生事件；n/100PY，每100患者年的患者数量；PY，患者年；UPA，乌帕替尼；TCS，外用糖皮质激素
图2 乌帕替尼治疗中国特应性皮炎人群长达4.3年的特别关注不良事件发生率（数据来源：参考文献6）
[1] 中华医学会皮肤性病学分会免疫学组. 特应性皮炎的全程管理共识[J]. 中华皮肤科杂志, 2023,56(1):5-15. doi: 10.35541/cjd.20220618.
[2] Abuabara K, Margolis DJ, Langan SM. The long-term course of atopic dermatitis[J]. Dermatol Clin, 2017,35(3):291-297. doi: 10.1016/j.det.2017.02.003.
[3] 中国医师协会皮肤科医师分会, 中华医学会皮肤性病学分会, 中国医疗保健国际交流促进会皮肤医学分会, 等. 特应性皮炎治疗药物应用管理专家共识（2024版）[J]. 中华皮肤科杂志, 2024,57(2):97-108. doi: 10.35541/cjd.20230358.
[4] Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials[J]. Lancet, 2021,397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2.
[5] Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2021,397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4.
[6] Gao X, Zhang J, Zhang C, et al. Long-term safety profile of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis among Chinese Subgroup of Measure Up 1 and AD Up Clinical Trials[C]. The 19th Annual Meeting of China Dermatologist Association, Wuhan, 2024.
[7] Wan J, Shin DB, Syed MN, et al. Malignancy risk in patients with atopic dermatitis: a population-based cohort study[J]. Br J Dermatol, 2023,189(1):53-61. doi: 10.1093/bjd/ljad072.
[8] Shukla S, Feldman SR, Strowd LC. A safety review of the medications used to treat atopic dermatitis[J]. Expert Opin Drug Saf, 2018,17(2):179-183. doi: 10.1080/14740338.2018.1411478.
[9] Mohamed MF, Bhatnagar S, Parmentier JM, et al. Upadacitinib: mechanism of action, clinical, and translational science[J]. Clin Transl Sci, 2024,17(1):e13688. doi: 10.1111/cts.13688.
[10] Clarke B, Yates M, Adas M, et al. The safety of JAK-1 inhibitors[J]. Rheumatology (Oxford), 2021,60(Suppl 2):ii24-ii30. doi: 10.1093/rheumatology/keaa895.
[11] Bunick C, Chovatiya R, Guttman E, et al. Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure[EB/OL]. The European Academy of Dermatology and Venereology congress, Paris, 2024. https://eadv-virtual-lms.m-anage.com/eadv/eadvcongress2024/en-GB/presentation/47137.
[12] Hagino T, Saeki H, Fujimoto E, et al. Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study[J]. J Dermatolog Treat, 2024,35(1):2344591. doi: 10.1080/09546634.2024.2344591.
[13] Chen Y, Cao Q, Peng C, et al. Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China[J]. Front Med, 2024,18(4):752-756. doi: 10.1007/s11684-024-1063-9.
[14] Manzar D, Nair N, Suntres E, et al. Systematic review and network meta-analysis of the risk of malignancy with biologic therapies and selective Janus kinase-1 inhibitors in atopic dermatitis[J]. Postepy Dermatol Alergol, 2024,41(3):270-275. doi: 10.5114/ada.2024.141125.
本材料仅供中国大陆境内的医疗卫生专业人员作为学术参考，而非针对一般公众，亦非广告用途。医疗卫生专业人员在做出任何与治疗有关的决定时，应根据患者的具体情况，参照药监局核准的药品说明书。如果您不是卫生医疗专业人士，请勿阅读和/或传播本材料。
